Amendments to Debt Facility with Avenue Capital Group
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Recce Pharmaceuticals Ltd. has announced amendments to its debt facility with Avenue Capital Group, extending the interest-only period to support ongoing clinical trials. In exchange for these amendments, Recce will issue additional warrants to Avenue Capital Group.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Notice of Annual General Meeting/Proxy Form
- Notification of cessation of securities - RCE
- Resolutions under section 249N of the Corporations Act
- 2026 Annual General Meeting
- Results of General Meeting
Later from Recce Pharmaceuticals
- Notification regarding unquoted securities - RCE
- Independent Review of Indonesian Phase 3 R327G Trial Data
- License and Commercialisation Agreement in AUS/NZ for R327G
- Quarterly Activities/Appendix 4C Cash Flow Report
- Application for quotation of securities - RCE
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals